At present, two PD-1 blocking antibodies, pembrolizumab and nivolumab, and the CTLA-4 receptor blocking antibody ipilimumab are approved by FDA for the treatment of dMMR/MSI-H CRC (49). Here, PDCD1 is linked to colorectal carcinoma.